Future growth expectations in earnings/operating earnings/profits/EPS?

Pharma CDMO and biologicals are new growth verticals targeting multi-billion-dollar markets with potential 20-25% CAGR over the next 2-3 years. Pharma business expected to breakeven and achieve critical mass (Rs. 500-750 crore revenues) in about 2 years. Biologicals segment is growing rapidly (25-30% growth expected next year), moving towards becoming a dominant player domestically and internationally. AgChem exports growing steadily, new products showing 35-40% growth YoY, helping sustain overall growth amid macro uncertainties. EBITDA margin improvement is structural due to superior product

Current/ Expected Orderbook/ Pending Orders?

The order book remains approximately at the same level, around USD 1.4 billion (Page 10). Growth is influenced not only by the order book but also by annual purchase orders and long-term agreements (Page 9). The company is maintaining and sustaining current volumes, with overall industry conditions being in transition due to trade wars, tariffs, and other challenges (Page 9). Clarity on growth visibility for FY26 or FY27 is expected in the next one or two quarters (Page 9).

Any current/future new fundraising through debt or equity?

No explicit mention of any current or planned new fundraising through debt or equity in the provided transcript. The company highlights a strong balance sheet with a healthy net cash balance of Rs. 42,091 million. They emphasize having the capacity to scale up and accelerate investments in new initiatives over the next two years. Investments are being made mainly from internal accruals for building differentiated capabilities in pharma, biologicals, and other verticals. No announcements or indications of fresh capital raising via equity or debt were discussed for the near future. The focus rem

Any current/future capex/capital investment/strategic investment?

PI Industries plans to invest in building two new multiproduct plants in the coming year to meet future business requirements. The capital expenditure (CAPEX) guidance for the next year is estimated between Rs. 800 to 1,000 crore. Pharma segment CAPEX includes investments in hardware, software, and regulatory compliance to build capabilities across the value chain; this investment phase will take a couple of years to generate significant value. The company is aggressively investing in scaling the Plant Health Care technology platform globally over the next two or more years. These capex initia

Future growth expectations in sales/revenue/volumes?

PI Industries expects growth in the agrochemical exports of around 9% year-on-year, with new product growth at 35-40% YoY. Domestic branded revenue is growing at about 5% with volume growth at 8%. The pharmaceutical CDMO segment is projected to grow 20-25% year-on-year over the next 2-3 years, though it is currently in a build-out/gestation phase. Biologicals segment is growing rapidly with a 25% increase over the prior year and expected 25-30% growth next year, aiming to become a top player domestically and expand globally. New verticals like pharma, biologics, and electronic chemicals are ex

IN US

Sale is live|00:00:00left today

P I Industries LtdQ4 FY26Fertilizers & Agrochemicals

P I Industries Ltd Q4 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹2,755P/E: 34.6Market Cap: ₹47.3K CrSector: Fertilizers & Agrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→PI Industries expects growth in the agrochemical exports of around 9% year-on-year, with new product growth at 35-40% YoY.
→Domestic branded revenue is growing at about 5% with volume growth at 8%.
→The pharmaceutical CDMO segment is projected to grow 20-25% year-on-year over the next 2-3 years, though it is currently in a build-out/gestation phase.
→Biologicals segment is growing rapidly with a 25% increase over the prior year and expected 25-30% growth next year, aiming to become a top player domestically and expand globally.
→New verticals like pharma, biologics, and electronic chemicals are expected to meaningfully contribute in 2-3 years.
→Agrochemical markets are mixed currently, but visibility is expected to improve in the next 1-2 quarters.
→CAPEX plans include building new multiproduct plants to support future growth with Rs. 800-1,000 crore planned for next year.

Margin guidance

Category 3

→Pharma CDMO and biologicals are new growth verticals targeting multi-billion-dollar markets with potential 20-25% CAGR over the next 2-3 years.
→Pharma business expected to breakeven and achieve critical mass (Rs. 500-750 crore revenues) in about 2 years.
→Biologicals segment is growing rapidly (25-30% growth expected next year), moving towards becoming a dominant player domestically and internationally.
→AgChem exports growing steadily, new products showing 35-40% growth YoY, helping sustain overall growth amid macro uncertainties.
→EBITDA margin improvement is structural due to superior product mix and cost efficiencies; pharma business currently in investment/build phase depressing near-term margins but expected to improve.
→Overall company targeting sustained 20-25% CAGR over two decades through diversification and innovation.
→Current small scale of pharma/biologicals means meaningful contributions expected in 2-3 years, reflecting long gestation business models with potential for significant positive earnings impact thereafter.

3 more insights locked — sign up free to unlock

Fundraise plans

→No explicit mention of any current or planned new fundraising through debt or equity in the provided transcript.
→The company highlights a strong balance sheet with a healthy net cash balance of Rs. 42,091 million.
→They emphasize having the capacity to scale up and accelerate investments in new initiatives over the next two years.
→Investments are being made mainly from internal accruals for building differentiated capabilities in pharma, biologicals, and other verticals.
→No announcements or indications of fresh capital raising via equity or debt were discussed for the near future.
→The focus remains on organic scaling and measured capital allocation rather than external fundraising.

Order book

→The order book remains approximately at the same level, around USD 1.4 billion (Page 10).
→Growth is influenced not only by the order book but also by annual purchase orders and long-term agreements (Page 9).
→The company is maintaining and sustaining current volumes, with overall industry conditions being in transition due to trade wars, tariffs, and other challenges (Page 9).
→Clarity on growth visibility for FY26 or FY27 is expected in the next one or two quarters (Page 9).

Capex plans

Yes

→PI Industries plans to invest in building two new multiproduct plants in the coming year to meet future business requirements.
→The capital expenditure (CAPEX) guidance for the next year is estimated between Rs. 800 to 1,000 crore.
→Pharma segment CAPEX includes investments in hardware, software, and regulatory compliance to build capabilities across the value chain; this investment phase will take a couple of years to generate significant value.
→The company is aggressively investing in scaling the Plant Health Care technology platform globally over the next two or more years.
→These capex initiatives are aimed at supporting growth in agrochemicals, pharma CDMO, biologicals, and specialty chemicals segments, positioning the company for long-term expansion across multiple verticals.

How does P I Industries Ltd rank vs peers in Fertilizers & Agrochemicals?

Pro feature

1P I Industries Ltd

Rev 3Mar 3

See full Fertilizers & Agrochemicals sector rankings

Want more stocks like P I Industries Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio